Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dicyclohexylcarbodiimide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dicyclohexylcarbodiimide SCHEMBL5967555 | 1.00 | EPHX1 (0.71) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL868032 | 0.86 | EPHX1 (0.71) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL28858414 | 0.85 | EPHX1 (0.88) | EPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL15667923 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL11842065 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL21986399 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL303 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL3173433 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL28613031 | 0.82 | EPHX1 (0.83) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL2784143 | 0.82 | EPHX1 (0.83) | EPHX1HIF1AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105622613-A | Method for synthesizing ibrutinib | AOPUTON (SHANGHAI) MEDICAL TECH CO LTD | 2016-06-01 | — | — | CN | claimed |
| CN-105566266-A | 15-ketone preparation method | NORTHEAST PHARMACEUTICAL GROUP CO LTD | 2016-05-11 | — | — | CN | claimed |
| EP-2091932-B1 | SEMI-SYNTHESIS AND ISOLATION OF TAXANE INTERMEDIATES FROM A MIXTURE OF TAXANES | CHATHAM BIOTEC LTD (CA) | 2013-12-11 | — | — | EP | claimed |
| US-7838694-B2 | Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes | CHATHAM BIOTEC, LIMITED (CA) | 2010-11-23 | — | — | US | claimed |
| CN-101104583-B | Technique for preparing diacerein by two-step oxidation process | SHANGHAI AUSPURE BIOTECHNOLOGY CO LTD | 2010-06-02 | — | — | CN | claimed |
| EP-2091932-A1 | SEMI-SYNTHESIS AND ISOLATION OF TAXANE INTERMEDIATES FROM A MIXTURE OF TAXANES | Chatham Biotec Ltd. (CA) | 2009-08-26 | — | — | EP | claimed |
| US-20080262250-A1 | Semi-Synthesis of Taxane Intermediates and Their Conversion to Paclitaxel and Docetaxel | CHATHAM BIOTEC, LIMITED (CA) | 2008-10-23 | — | — | US | claimed |
| US-20080146824-A1 | Preparation of paclitaxel and docetaxel, 10-deacetylbaccatin III and baccatin III; antileukemic and tumor inhibitory activity | CHATHAM BIOTEC, LIMITED (CA) | 2008-06-19 | — | — | US | claimed |
| EP-1814868-A1 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | Chatham Biotec Ltd. (CA) | 2007-08-08 | — | — | EP | claimed |
| US-20070073069-A1 | Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes | INNOVATIONAL HOLDINGS LLC | 2007-03-29 | — | — | US | claimed |
| US-20070032668-A1 | Semi-synthesis of taxane intermediates from a mixture of taxanes | INNOVATIONAL HOLDINGS LLC | 2007-02-08 | — | — | US | claimed |
| US-20070027207-A1 | Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel | INNOVATIONAL HOLDINGS LLC | 2007-02-01 | — | — | US | claimed |
| CN-1800198-A | Method for preparing macrolides half-synthesized antibiotics telithromycin | UNIV CHINA PHARMA (CN) | 2006-07-12 | — | — | CN | claimed |
| WO-2005118563-A1 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | CHATHAM BIOTEC LTD. (CA) | 2005-12-15 | — | — | WO | claimed |
| US-20050272807-A1 | Using protected taxane chemical intermediates; beta-lactam oxazolidine, or oxazoline as blocking agents | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-12-08 | — | — | US | claimed |
| WO-2005105767-A1 | SEMI-SYNTHESIS AND ISOLATION OF TAXANE INTERMEDIATES FROM A MIXTURE OF TAXANES | CHATHAM BIOTEC LTD. (CA) | 2005-11-10 | — | — | WO | claimed |
| US-20050250954-A1 | Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-11-10 | — | — | US | claimed |
| US-20050240036-A1 | Semi-synthesis of taxane intermediates from a mixture of taxanes | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-10-27 | — | — | US | claimed |
| CN-116348460-A | Preparation method of BTK degradation agent | 四川海思科制药有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-3957794-A | 3-Amino-2,3,3a,6,7,7a-hexahydro-thieno[3,2-b]pyridin-(4H)5-one | HOFFMANN-LA ROCHE INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027207-A1 | Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel | DHPS, COASY, SUB1 | EPHX1 2904/4885HIF1A 2591/4885ALDH1A1 2291/4885 |
| US-20050272807-A1 | Using protected taxane chemical intermediates; beta-lactam oxazolidine, or oxazoline as blocking agents | TOP2B, TOP1, TOP2A | EPHX1 1996/4885HIF1A 3286/4885ALDH1A1 1077/4885 |
| US-20070032668-A1 | Semi-synthesis of taxane intermediates from a mixture of taxanes | TUBB3, TBCA, TUBB6 | EPHX1 4499/4885HIF1A 4498/4885ALDH1A1 2893/4885 |
| US-20050240036-A1 | Semi-synthesis of taxane intermediates from a mixture of taxanes | TUBB3, TBCA, TUBB6 | EPHX1 4499/4885HIF1A 4498/4885ALDH1A1 2893/4885 |
| US-20080262250-A1 | Semi-Synthesis of Taxane Intermediates and Their Conversion to Paclitaxel and Docetaxel | DHPS, COASY, SUB1 | EPHX1 2904/4885HIF1A 2591/4885ALDH1A1 2291/4885 |
| US-20070073069-A1 | Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes | TUBB3, TUBB6, TUBA1B | EPHX1 4443/4885HIF1A 4037/4885ALDH1A1 3484/4885 |
| US-20080146824-A1 | Preparation of paclitaxel and docetaxel, 10-deacetylbaccatin III and baccatin III; antileukemic and tumor inhibitory activity | TUBB3, BBC3, TUBA3C | EPHX1 4589/4885HIF1A 4035/4885ALDH1A1 3807/4885 |
| US-20050250954-A1 | Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes | TUBB3, TUBB6, TUBA1B | EPHX1 4443/4885HIF1A 4037/4885ALDH1A1 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.